Biopharma Quarterly Dealmaking Statistics, Q3 2019
A Look At Financing, M&A And Alliance Activity July-September 2019
Executive Summary
During Q3, biopharma company fundraising reached $13.3bn, mostly from follow-on public offerings, which again made up the most of those dollars. Despite numerous deals valued at $100m+, M&A activity was the lowest of the year. Many of the biggest partnership deals were centered around the inflammation/immune area.
You may also be interested in...
Sobi Targets Thrombocytopenia In $915m Swoop For Dova
The Swedish group has got hold of the ITP and CLD drug Doptelet, widening its hematology business beyond hemophilia.
Henlius Biotech IPO Raises Below-Target $410m
Shares of China’s Shanghai Henlius Biotech will debut on the Hong Kong stock exchange later this week after the company collected $410m in an IPO that was priced at the bottom end of the targeted range.
Lundbeck CEO: Alder Buy Will Boost Pipeline
Deborah Dunsire tells Scrip that buying Alder offers Lundbeck a blockbuster prevention treatment for severe migraine patients, and helps rebuild Danish group’s prospects.